Pages

Thursday, May 22, 2014

Asterias Biotherapeutics, Inc. Announces New Results From...

Asterias Biotherapeutics presented today the results of its Phase 1 clinical trial assessing the safety of its product, AST-OPC1, in subjects with spinal cord injury.

http://ift.tt/1nvlO0z

No comments:

Post a Comment